Reaction
Tuberculin Test Positive reporting signals
As of the last recalculation, Tuberculin Test Positive appears in 2,533 FAERS reports alongside 28 co-occurring drug terms. The strongest observed disproportionality signal is ISONIAZID (PRR 39.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Isoniazid | 76 | 39.7 | 39.9 |
| Minocycline | 34 | 24.3 | 24.3 |
| Leflunomide | 254 | 22.1 | 22.1 |
| Adalimumab | 1,044 | 19.9 | 20.0 |
| Hydroxychloroquine Sulfate | 200 | 19.5 | 19.5 |
| Tofacitinib | 358 | 18.4 | 18.4 |
| Sulfasalazine | 154 | 17.2 | 17.2 |
| Etanercept | 660 | 11.9 | 11.9 |
| Methotrexate Sodium | 549 | 11.6 | 11.6 |
| Methotrexate | 460 | 10.8 | 10.8 |
| Abatacept | 164 | 10.3 | 10.3 |
| Hydroxychloroquine | 81 | 9.2 | 9.2 |
| Ustekinumab | 100 | 8.3 | 8.3 |
| Infliximab | 200 | 8.1 | 8.1 |
| Certolizumab Pegol | 107 | 7.8 | 7.8 |
| Ixekizumab | 32 | 7.2 | 7.2 |
| Tocilizumab | 94 | 7.0 | 7.0 |
| Adalimumab-Fkjp | 32 | 5.7 | 5.7 |
| Rifampin | 10 | 5.6 | 5.7 |
| Baricitinib | 5 | 4.3 | 4.3 |
| Secukinumab | 80 | 4.2 | 4.2 |
| Linezolid | 15 | 4.2 | 4.2 |
| Golimumab | 39 | 3.8 | 3.8 |
| Ocrelizumab | 24 | 3.2 | 3.2 |
| Diclofenac Potassium, Film Coated | 3 | 2.9 | 2.9 |
| Diclofenac Potassium Tablets | 3 | 2.9 | 2.9 |
| Risankizumab-Rzaa | 27 | 2.7 | 2.7 |
| Guselkumab | 6 | 1.4 | 1.4 |